Apellis Pharmaceuticals (NASDAQ: APLS) is a global biopharmaceutical company known for its pioneering work in complement science. The company focuses on developing therapies for challenging diseases and has introduced a new class of complement medicine, the first in 15 years. Apellis has two C3-targeting medicines approved for treating four serious diseases, showcasing its innovative approach in the pharmaceutical industry.
On February 24, 2026, Apellis is set to release its quarterly earnings. Wall Street estimates the earnings per share to be -$0.39, while analysts predict a slightly larger loss of -$0.41 per share. Revenue projections are close, with Wall Street estimating $199.4 million and analysts expecting $199 million. The earnings call is scheduled for 8:30 AM ET, where management will discuss business conditions and future expectations.
Currently, APLS stock trades at $22.28, reflecting a 2.3% decrease. The company has a market capitalization of $2.82 billion and a price-to-earnings ratio of 71.87. The stock's fifty-day simple moving average is $23.31, while the two-hundred-day simple moving average is $23.87. Over the past year, the stock has fluctuated between a low of $16.10 and a high of $30.48.
Financially, Apellis maintains a quick ratio of 3.10 and a current ratio of 3.54, indicating strong liquidity. The debt-to-equity ratio is 0.90, showing moderate financial leverage. The company's price-to-sales ratio is 2.77, and the enterprise value to sales ratio is also 2.77, reflecting its market value compared to sales. The enterprise value to operating cash flow ratio is 35.70, suggesting the company's ability to generate cash from operations.
The upcoming earnings report is crucial for APLS as it could influence the stock's near-term price movement. If the actual results surpass expectations, the stock might see an upward trend. Conversely, a miss in expectations could lead to a decline in stock price. The sustainability of any immediate price changes will depend on the management's discussion during the earnings call.
